Wall Street Zen Upgrades Inovio Pharmaceuticals (NASDAQ:INO) to "Hold"

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Friday.

Other equities analysts have also issued research reports about the stock. Oppenheimer reduced their target price on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a report on Wednesday, May 14th. Royal Bank Of Canada restated a "sector perform" rating and set a $5.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th. Finally, HC Wainwright restated a "neutral" rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a report on Wednesday, March 19th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $9.75.

Inovio Pharmaceuticals Trading Down 6.2%

Shares of INO traded down $0.14 during mid-day trading on Friday, reaching $2.11. The company had a trading volume of 4,781,200 shares, compared to its average volume of 638,774. The stock has a market cap of $77.37 million, a price-to-earnings ratio of -0.66 and a beta of 1.34. The firm has a fifty day simple moving average of $1.99 and a 200-day simple moving average of $1.96. Inovio Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $12.33.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts' consensus estimates of ($0.74) by $0.23. The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.01 million. As a group, equities analysts predict that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Barclays PLC increased its stake in Inovio Pharmaceuticals by 15.0% during the 4th quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 5,111 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 5,894 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Inovio Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company's stock worth $1,150,000 after purchasing an additional 6,874 shares during the last quarter. Northern Trust Corp increased its position in shares of Inovio Pharmaceuticals by 6.4% in the 4th quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company's stock worth $401,000 after purchasing an additional 13,269 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Inovio Pharmaceuticals by 22.4% in the 1st quarter. Bank of New York Mellon Corp now owns 75,422 shares of the biopharmaceutical company's stock worth $123,000 after purchasing an additional 13,784 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.